5-Tert-butyl-3-chloro-1,2-oxazole | 1781653-56-2

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 英文名称: 5-Tert-butyl-3-chloro-1,2-oxazole
• CAS: 1781653-56-2
• 化学式: C₇H₁₀ClNO
• 分子量: 159.61
• InChiKey: WCPFUBDCGNHGNE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• PYRIDONE COMPOUNDS AND AGRICULTURAL AND HORTICULTURAL FUNGICIDES CONTAINING THE SAME AS ACTIVE INGREDIENTS
  申请人：MITSUI CHEMICALS AGRO, INC.

  公开号：US20200196600A1

  公开（公告）日：2020-06-25

  A pyridone compound represented by Formula (1): wherein R1, R2, X, Y and Z are defined. The pyridone compound can control plant diseases.

  一种由化学式（1）表示的吡啶酮化合物：其中R1、R2、X、Y和Z被定义。该吡啶酮化合物可以控制植物疾病。
• Pyridone compounds and agricultural and horticultural fungicides containing the same as active ingredients
  申请人：MITSUI CHEMICALS AGRO, INC.

  公开号：US11000038B2

  公开（公告）日：2021-05-11

  A pyridone compound represented by Formula (1): wherein R1, R2, X, Y and Z are defined. The pyridone compound can control plant diseases.

  由式（1）代表的吡啶酮化合物：其中 R1、R2、X、Y 和 Z 已定义。 吡啶酮化合物可防治植物病害。
• Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines
  申请人：Centre National de la Recherche Scientifique (CNRS)

  公开号：US11046657B2

  公开（公告）日：2021-06-29

  A subject of the present invention is a compound having the general formula (I): a pharmaceutically acceptable salt thereof or a tautomeric form thereof, wherein A, B3, B4, B5, Y, X, B1 and B2 are as defined in any one of claims 1 to 10. Another subject of the invention is the compound as defined above for use as a medicament, in particular for preventing and/or treating inflammation and inflammatory diseases, immune and auto-immune diseases, pain related diseases, genetic diseases and/or cancer.

  本发明的一个主题是具有通式 (I) 的化合物： 其药学上可接受的盐或其同分异构体、 其中 A、B3、B4、B5、Y、X、B1 和 B2 如权利要求 1 至 10 中任一项所定义。 本发明的另一个主题是上文定义的化合物，可用作药物，特别是用于预防和/或治疗炎症和炎症性疾病、免疫和自身免疫性疾病、疼痛相关疾病、遗传性疾病和/或癌症。
• Pyrimidinone Derivatives and Uses Thereof to Neutralize the Biological Activity of Chemokines
  申请人：Centre National de la Recherche Scientifique (CNRS

  公开号：US20200181093A1

  公开（公告）日：2020-06-11

  A subject of the present invention is a compound having the general formula (I): a pharmaceutically acceptable salt thereof or a tautomeric form thereof, wherein A, B 3 , B 4 , B 5 , Y, X, B 1 and B 2 are as defined in any one of claims 1 to 10. Another subject of the invention is the compound as defined above for use as a medicament, in particular for preventing and/or treating inflammation and inflammatory diseases, immune and auto-immune diseases, pain related diseases, genetic diseases and/or cancer.
• [EN] PYRIDIN-2-ONE COMPOUNDS USEFUL AS SMARCA2 ANTAGONISTS<br/>[FR] COMPOSÉS DE PYRIDIN-2-ONE UTILES EN TANT QU'ANTAGONISTES DE SMARCA2
  申请人：EPIZYME INC

  公开号：WO2020023657A1

  公开（公告）日：2020-01-30

  This disclosure generally relates to pyridine-2-one compounds of formula (I) and methods of using them in the treatment of a disorder, such as cancer or a SMARCA2-associated disorder, including as antagonists (e.g., inhibitors) of SMARCA2. The present disclosure provides treatment modalities, e.g., strategies, treatment methods, patient stratification methods, compounds, combinations, and compositions that are useful for the treatment of disorders, e.g., proliferative disorders, such as certain cancers. Some aspects of this disclosure provide treatment modalities, methods, strategies, compounds, compositions, combinations, and dosage forms for the treatment of cell proliferative disorders, e.g., cancers with decreased activity or function, or loss of function, of SMARCA4 with a SMARCA2 antagonist.